These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Common side effects of anti-EGFR therapy: acneform rash. Sipples R Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):28-34. PubMed ID: 16616284 [TBL] [Abstract][Full Text] [Related]
23. Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption. Takata T; Tarutani M; Zouboulis CC; Sano S J Dermatol Sci; 2012 May; 66(2):165-8. PubMed ID: 22440861 [No Abstract] [Full Text] [Related]
24. EGFR-targeted therapy and related skin toxicity. Morse L; Calarese P Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744 [TBL] [Abstract][Full Text] [Related]
25. Erlotinib associated with rosacea-like folliculitis and Malassezia sympodialis. Cuétara MS; Aguilar A; Martin L; Aspiroz C; del Palacio A Br J Dermatol; 2006 Aug; 155(2):477-9. PubMed ID: 16882195 [No Abstract] [Full Text] [Related]
26. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Jacot W; Bessis D; Jorda E; Ychou M; Fabbro M; Pujol JL; Guillot B Br J Dermatol; 2004 Jul; 151(1):238-41. PubMed ID: 15270903 [No Abstract] [Full Text] [Related]
33. Cetuximab-induced acneiform eruption and the response to isotretinoin. Vezzoli P; Marzano AV; Onida F; Alessi E; Galassi B; Tomirotti M; Berti E Acta Derm Venereol; 2008; 88(1):84-6. PubMed ID: 18176767 [No Abstract] [Full Text] [Related]
34. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Gerber PA; Kukova G; Buhren BA; Homey B Dermatology; 2011; 222(2):144-7. PubMed ID: 21346311 [TBL] [Abstract][Full Text] [Related]
35. The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome. Lacouture ME; Lai SE Br J Dermatol; 2006 Oct; 155(4):852-4. PubMed ID: 16965448 [No Abstract] [Full Text] [Related]
36. Dimorphic cutaneous manifestation of a toxic eruption due to erlotinib therapy. Campbell TM; Brown CW J Drugs Dermatol; 2008 Dec; 7(12):1161-3. PubMed ID: 19137770 [TBL] [Abstract][Full Text] [Related]
37. A man whose scapula was spared a drug-associated rash. Sanz A; del Valle ML CMAJ; 2005 Mar; 172(6):745. PubMed ID: 15767607 [No Abstract] [Full Text] [Related]
38. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370 [TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes. Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818 [TBL] [Abstract][Full Text] [Related]
40. Livedo reticularis with retiform purpura associated with gefitinib (Iressa). Blume JE; Miller CC Int J Dermatol; 2007 Dec; 46(12):1307-8. PubMed ID: 18173531 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]